PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway
Titel:
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway
Auteur:
Ni, Jie Zhou, Lei-lei Ding, Li Zhao, Xia Cao, Haixia Fan, Fan Li, Huizi Lou, Rui Du, Yuanyuan Dong, Shuchen Liu, Siwen Wang, Zhuo Ma, Rong Wu, Jianzhong Feng, Jifeng